Analysis of Lexeo Therapeutics Inc (LXEO)’s performance, earnings and valuation

Lexeo Therapeutics Inc [LXEO] stock is trading at $3.24, up 20.00%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LXEO shares have gain 20.45% over the last week, with a monthly amount glided 42.11%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Lexeo Therapeutics Inc [NASDAQ: LXEO] stock has seen the most recent analyst activity on June 13, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $28. Previously, H.C. Wainwright started tracking the stock with Buy rating on June 06, 2024, and set its price target to $22. On November 28, 2023, Stifel initiated with a Buy rating and assigned a price target of $20 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $22 on November 28, 2023. Leerink Partners initiated its recommendation with a Outperform and recommended $19 as its price target on November 28, 2023. JP Morgan started tracking with a Overweight rating for this stock on November 28, 2023, and assigned it a price target of $20. In a note dated November 28, 2023, Chardan Capital Markets initiated an Buy rating and provided a target price of $23 on this stock.

Lexeo Therapeutics Inc [LXEO] stock has fluctuated between $1.45 and $19.50 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Lexeo Therapeutics Inc [NASDAQ: LXEO] shares were valued at $3.24 at the most recent close of the market. An investor can expect a potential return of 764.2% based on the average LXEO price forecast.

Analyzing the LXEO fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -0.87, Equity is -0.86 and Total Capital is -0.87. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.78 points at the first support level, and at 2.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.59, and for the 2nd resistance point, it is at 3.93.

Ratios To Look Out For

For context, Lexeo Therapeutics Inc’s Current Ratio is 3.42. Also, the Quick Ratio is 3.42, while the Cash Ratio stands at 0.94.

Transactions by insiders

Recent insider trading involved Townsend Richard Nolan, Officer, that happened on May 16 ’25 when 1074.0 shares were purchased. Officer, Robertson Jenny completed a deal on May 16 ’25 to buy 521.0 shares. Meanwhile, Officer See Tai Sandi bought 367.0 shares on May 16 ’25.

Related Posts